CogState (CGS.AX) Akcija Cena
CogState Cena
Pēdējos 19 gados CogState ieņēmumi auga par 20,0 % gadā un sasniedza 53,09 M USD. Peļņa uz akciju auga par 8,5 % gadā pēdējos 16 gados. CogState neto marža 19,1 % ir pieaugusi salīdzinājumā ar 16,0 % pirms dažiem gadiem. Pie šodienas cenas dividenžu ienesīgums ir aptuveni 1,19 %. Izmaksas koeficients ir ap 34 % no peļņas. CogState 12 mēnešu konsensa mērķa cena ir 2,15 USD, ap zem kursu par 10,6 %. No 6 analītiķiem 5 iesaka pirkt — kopējais konsenss ir Pirkt.
CogState akcijas cena
CogState biznesa modelis un akciju analīze
Bieži uzdotie jautājumi par CogState akciju
CogState Ltd is a leading provider of cognitive testing services for clinical trials, academic research, and healthcare. The company's business model revolves around using their digital tools and technologies to measure and enhance cognitive function in patients. By collaborating with pharmaceutical companies, academic institutions, and healthcare organizations, CogState Ltd aims to improve patient outcomes and accelerate the development of new treatments. With their expertise and extensive database, CogState Ltd offers customized solutions and prognostic insights to address the cognitive challenges faced in various industries.
CogState Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.
CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.
CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.
CogState Ltd is primarily present in Australia, the United States, and Europe.
CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.
Analītiķi pašlaik nosaka vidējo CogState akcijas mērķa cenu 2,15 USD (mediāna: 2,15 USD), kas ir -10,6 % pret pēdējo cenu. Konsenss balstās uz 6 analītiķu vērtējumiem.
7 analītiķi pašlaik vērtē CogState akciju: 6 iesaka pirkt, 1 turēt un 0 pārdot. 2026. gadam analītiķi sagaida, ka CogState gūs 128,65 M USD ieņēmumus un 0,09 USD peļņu uz akciju.
Pēc pašreizējā kursa CogState akcija maksā 2,14 EUR (2,40 USD).
CogState akcija (CGS.AX) tiek kotēta 2 biržās, tostarp: ASX (CGS.AX).
CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.
gaidāmā apgrozījums CogState ir 128,65 M USD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.
gaidāmā peļņa CogState ir 16,22 M USD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.
CogState cenas un peļņas rādītājs (P/E) pašlaik ir 25,75. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt CogState akcijas vērtību.
CogState cenas un apgrozījuma rādītājs (P/S) pašlaik ir 3,25. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā CogState akcijas vērtības mērs.
CogState Eulerpool kvalitātes rādītājs ir 6/10.
CogState ISIN ir AU000000CGS8. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.
CogState tikeris ir CGS.AX. Tikeris tiek izmantots CogState akciju tirdzniecībai biržā.
CogState akcija
CogState Salīdzināmo uzņēmumu grupa
CogState Biržas kods
CogState FIGI
Visi CogState fundamentālie rādītāji un padziļinātā analīze
Mūsu akciju analīze par CogState ietver svarīgus finanšu rādītājus, piemēram, apgrozījumu, peļņu, P/E rādītāju, P/S rādītāju, EBIT, kā arī informāciju par dividendēm. Turklāt mēs aplūkojam aspektus kā akcijas, tirgus kapitalizāciju, parādus, pašu kapitālu un saistības no CogState. Ja meklējat sīkāku informāciju par šīm tēmām, piedāvājam detalizētas analīzes mūsu apakšlapās: